



Matt Angle, PhD

Founder & Chief Executive Officer
Paradromics

Matt Angle is the Founder and CEO of Paradromics, a neurotechnology leader developing the world's most advanced and clinically viable brain-computer interface (BCI) platform – bridging human thought and digital capability.

He earned his PhD in Neuroscience from the University of Heidelberg, followed by postdoctoral research at Stanford University's Department of Materials Science and Engineering, where he pioneered next-generation electronics for large-scale, high-fidelity neural recordings.

Recognizing the urgent need for a BCI platform engineered for long-term clinical use and capable of capturing brain activity at unprecedented data rates, Matt founded Paradromics, securing competitive NIH and DARPA contracts to advance the core neurotechnology.

In 2019, under Matt's leadership, Paradromics initiated development of its first clinical product, the Connexus® BCI, recipient of two FDA Breakthrough Device Designations, which achieved its first-in-human neural recording in May 2025. Paradromics has since completed its first implantation of the Connexus BCI in a clinical trial participant, marking a major milestone in the company's FDA-approved Connect-One Clinical Study – now underway to evaluate the device's long-term safety, performance, and patient impact.

By enabling direct, high-bandwidth data exchange with the brain, the Paradromics platform is poised to transform care for a wide spectrum of neurological and psychiatric conditions – from paralysis and movement disorders to chronic pain, addiction, depression, and beyond – delivering real-time, precision digital medicine at scale.

Matt is also a founding charter member of the Implantable Brain-Computer Interface Collaborative Community (iBCI-CC) and a member of the Advisory Council for the Institute of Neuroethics.

